EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies

Tavus Atajanova, Md Mahfuzur Rahman, David J Konieczkowski, Zachary S Morris

Cancer Immunology, Immunotherapy · 2023-11 · 72 (11) · 3445-3452

DOI: 10.1007/s00262-023-03532-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 02.09.2023. Verfasst von Tavus Atajanova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry and Biophysics Program, Amherst College, Amherst, MA, 01002, USA. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiation is commonly used as a treatment intended to cure or palliate cancer patients. Despite remarkable advances in the precision of radiotherapy delivery, even the most advanced forms inevitably expose some healthy tissues surrounding the target site to radiation. On rare occasions, this results in the development of radiation-associated secondary malignancies (RASM). RASM are typically high-grade and carry a poorer prognosis than their non-radiated counterparts. RASM are characterized by a high mutation burden, increased T cell infiltration, and a microenvironment that bears unique inflammatory signatures of prior radiation, including increased expression of various cytokines (e.g., TGF-β, TNF-α, IL4, and IL10). Interestingly, these cytokines have been shown to up-regulate the expression of PD-1 and/or PD-L1-an immune checkpoint receptor/ligand pair that is commonly targeted by immune checkpoint blocking immunotherapies. Here, we review the current understanding of the tumor-immune interactions in RASM, highlight the distinct clinical and molecular characteristics of RASM that may render them immunologically "hot," and propose a rationale for the formal testing of immune checkpoint blockade as a treatment approach for patients with RASM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsHumansT-LymphocytesCytokinesTumor MicroenvironmentB7-H1 Antigen

Stichwörter der Autor:innen

CytokinesImmunotherapyRadiationSecondary malignancies

Substanzen

CytokinesB7-H1 Antigen

Autor:innen und Institutionen

  • Biochemistry and Biophysics Program, Amherst College, Amherst, MA, 01002, USA.
  • Department of Sociology, Amherst College, Amherst, MA, 01002, USA.
  • Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, 53726, USA.
  • Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA.
  • Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, 53726, USA. zmorris@humonc.wisc.edu.

Zitieren

APA

Atajanova, T., Rahman, M. M., Konieczkowski, D. J., & Morris, Z. S. (2023). Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies. Cancer Immunology, Immunotherapy, 72(11), 3445-3452. https://doi.org/10.1007/s00262-023-03532-1

Vancouver

Atajanova T, Rahman MM, Konieczkowski DJ, Morris ZS. Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies. Cancer Immunology, Immunotherapy. 2023;72(11):3445-3452. doi:10.1007/s00262-023-03532-1

BibTeX
@article{Atajanova2023,
  author = {Atajanova, Tavus and Rahman, Md Mahfuzur and Konieczkowski, David J and Morris, Zachary S},
  title = {Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {11},
  pages = {3445--3452},
  doi = {10.1007/s00262-023-03532-1}
}
Kostenlos starten →